Imugene Doses First Patient in BTKi Combo Cohort of Azer-cel Trial

First Patient Dosed in BTKi Combination Cohort

Imugene Limited (ASX:IMU) has taken a significant step in its Phase 1b azer-cel clinical trial by dosing the first patient in the Bruton Tyrosine Kinase inhibitor (BTKi) combination cohort. This patient, diagnosed with mantle cell lymphoma (MCL) and having failed prior BTKi therapy, is being treated at Baylor University in Waco, Texas, a respected centre for oncology research. The addition of this cohort aims to evaluate whether combining azer-cel, an off-the-shelf allogeneic CAR T cell therapy, with BTKi treatment can improve outcomes for patients with B-cell malignancies who have limited options after BTKi resistance.

Addressing Resistance in B-Cell Malignancies

BTKi therapies have become a standard of care for several B-cell cancers, including follicular lymphoma, chronic lymphocytic leukemia, and mantle cell lymphoma. However, resistance or intolerance to BTKi drugs remains a major clinical hurdle. Imugene’s approach of concurrent dosing with azer-cel seeks to overcome this challenge by potentially enhancing the activity of both treatments. Enrolment in this cohort is underway across ten US and five Australian sites, reflecting the company’s global clinical footprint and ambition to address a pressing unmet need.

Expanding Clinical and Commercial Horizons

The BTKi combination cohort not only broadens the clinical scope of the azer-cel program but also positions Imugene to prioritise indications demonstrating the strongest clinical potential. This disciplined strategy supports capital-efficient development and may open doors for future partnerships or collaborations. The global BTKi market, valued at approximately US$12 billion in 2025, underscores the commercial significance of therapies targeting this pathway. CEO Leslie Chong emphasised the importance of this step, highlighting the potential to address a significant patient population with limited treatment options.

Promising Early Data and Ongoing Trial Progress

Previous cohorts in the azer-cel Phase 1b trial have shown encouraging results, with safety profiles that are manageable and evidence of durable clinical responses. Notably, the CAR T-naïve cohort recently reported an 81% overall response rate, demonstrating azer-cel’s potential across multiple lymphoma subtypes. This momentum supports the rationale for exploring combination therapies in more resistant populations. The trial’s multi-centre design across the US and Australia reflects Imugene’s commitment to robust data generation and regulatory engagement. The company plans to update the market with safety and preliminary efficacy data as patients in the BTKi cohort become evaluable, continuing to build its clinical evidence base 81% overall response rate.

Capital and Strategic Foundations for Growth

Backing this clinical expansion is Imugene’s recent $20 million capital raise, which has bolstered its balance sheet to support the ongoing azer-cel program. The funds are earmarked for advancing clinical trials and general working capital, reflecting a strategic push to accelerate development timelines and optimise trial design. This financial foundation complements the company’s clinical progress and supports its ambition to become a leader in allogeneic CAR T therapies for blood cancers $20 million capital raise.